Klotho
alpha-Klotho, sKlotho, long-release recombinant Klotho
Klotho (alpha-Klotho, sKlotho, long-release recombinant Klotho) is a longevity & bioregulators research compound. Alpha-Klotho is an anti-ageing protein made mostly in the kidney and the choroid plexus. A soluble form is shed into blood and CSF. It is the obligate co-receptor that lets FGF23 signal, which is how it governs phosphate and vitamin D handling, and separately it dampens insulin/IGF-1 and Wnt signaling and raises resistance to oxidative stress. Klotho falls with age and falls further in chronic kidney disease.
Klotho quick facts
| Reported research dose | 20mcg vial — see the full breakdown; no human dose exists |
| Route | Subcutaneous |
| Frequency | Undefined |
| Half-life | Native soluble Klotho is cleared within hours; the LR construct carries an albumin-binding group intended to hold cellular activity for up to ~19 days (vendor claim, not independently published) |
| Forms | Injectable |
| Evidence level | Theoretical — no human administration data |
The mouse genetics here are about as strong as ageing biology gets — and there is still not one human administration study. Treat any number as an extrapolation. It is also 20mcg, not milligrams: this is a protein dosed a thousand-fold lower than the peptides next to it, and confusing the units would be the dangerous error.
How Klotho works
Alpha-Klotho is an anti-ageing protein made mostly in the kidney and the choroid plexus. A soluble form is shed into blood and CSF. It is the obligate co-receptor that lets FGF23 signal, which is how it governs phosphate and vitamin D handling, and separately it dampens insulin/IGF-1 and Wnt signaling and raises resistance to oxidative stress. Klotho falls with age and falls further in chronic kidney disease.
Proposed benefits
Cognitive ageing, kidney and vascular health, and lifespan — on mouse genetics and one primate study, with no human administration data at all.
Where to get Klotho
Buy Klotho at Biolongevity Labs →Bacteriostatic water is the diluent — sterile water with 0.9% benzyl alcohol, which is what lets a vial be drawn from more than once. It does not come with the vial, and unlike the compound it is bought again every time.
Need bacteriostatic water? Get it at AminoWell USA (my company) → Code CAMERON.
The evidence for Klotho
Graded by what exists behind each claim.
Human clinical evidence
- No randomized human trials — a research compound with no commercial route to funding one, so the correlative and theoretical tiers are the evidence base rather than a consolation prize.
📊 Correlative data
- Low circulating Klotho tracks with almost everything that gets worse with age. Observational cohorts link lower serum alpha-Klotho to chronic kidney disease progression, cardiovascular events, arterial stiffening, and poorer cognitive scores. These are associations in people who were never given Klotho, and low Klotho is downstream of kidney damage — so a large part of the signal may be reporting kidney health rather than an independent effect.
- A common variant of the KL gene (the KL-VS haplotype) associates with higher circulating Klotho and, in several cohorts, with better cognitive ageing and longer life in carriers of one copy. Notably the effect is not linear — two copies do not do better than one, which argues against reading it as a simple more-is-better dose response.
🧪 How the mechanism reads
- The mouse genetics are unusually clean, in both directions. Disrupting Klotho produces a syndrome that looks like accelerated ageing — short lifespan, vascular calcification, osteoporosis, skin atrophy — and overexpressing it extends mouse lifespan. Two-way evidence like that is rare and is the whole reason anyone cares about this protein.
- A 2023 primate study reported that a single low systemic dose of Klotho improved cognitive performance in aged rhesus monkeys, and — importantly — that a higher dose did not. A non-monotonic dose response is the opposite of what most people assume when they scale a peptide up, and it means 'more' is a specific hypothesis to test, not a safe default.
- Mechanistically it sits upstream of several pathways already targeted elsewhere in this Vault: it is required for FGF23 signaling, it suppresses insulin/IGF-1 signaling, and it inhibits Wnt. That breadth is what makes it interesting and also what makes off-target effects hard to predict.
- Nothing here has been tested in a human being. Every number for human use is an extrapolation across two species boundaries.
Why an empty tier is not a verdict →
How to read these tiers: they say how much human evidence exists, not how well something works — and ✗ flags harm, never a disappointing trial. How the evidence tiers work →
What Klotho actually does
The first thing to understand about Klotho is its size, because almost everything else follows from it. Klotho is not a peptide. The reviewed UniProt record for human Klotho is 1,012 amino acids, with a signal peptide at residues 1–33, a transmembrane helix at 982–1002, and two glycosyl hydrolase family 1 regions spanning residues 57–506 and 515–953; it carries the enzyme classification EC 3.2.1.31 UniProt Q9UEF7 2026. That is a large, glycosylated, single-pass membrane protein with two enzyme-like domains — a completely different manufacturing, stability and delivery problem from anything else in this Vault.
There are two Klothos and conflating them is the commonest error made about it. Membrane Klotho, anchored by that transmembrane helix, is an obligate co-receptor: FGF23 binds FGF receptors with very low affinity on their own, and Klotho is what confers the affinity and the tissue specificity. That complex is how the kidney is told to excrete phosphate. Soluble Klotho is the ectodomain, cleaved off by membrane sheddases and released into blood, cerebrospinal fluid and urine, where it acts as a circulating factor in its own right Prud'homme 2022.
What soluble Klotho does that has nothing to do with FGF23. Its two glycoside-hydrolase-like domains UniProt Q9UEF7 2026 act on the sugar chains of proteins at the cell surface — modifying calcium and potassium channels and altering how long they stay in the membrane. Separately it dampens insulin/IGF-1 signaling, inhibits Wnt signaling and antagonizes TGF-beta. Reduced insulin/IGF-1 signaling is the single most reproducible longevity mechanism across species, which is why a circulating protein that damps it attracts the attention it does Prud'homme 2022.
Where it comes from, and what that implies clinically. The kidney is the dominant source. Chronic kidney disease is therefore a Klotho-deficient state, and the relationship between Klotho, FGF23, phosphate and vascular calcification is the reason a European renal working group produced a full review of Klotho as a therapeutic target Kanbay 2024. The best-characterized Klotho biology in humans is nephrology, not longevity, and the longevity claims are downstream of it.
And the brain, where the interest is sharpest. Klotho is expressed in the choroid plexus and is present in cerebrospinal fluid; the case for exploiting its neuroprotective effects against aging- and neurodegeneration-related cognitive dysfunction has been set out in detail Hanson 2021. A 1,012-residue glycoprotein does not cross the blood-brain barrier from a subcutaneous injection, and no published work says it does.
Cell, rodent, human — and where it stops
Step one, the protein: fully characterized. Sequence, domains, membrane topology and enzyme classification are in a reviewed database record UniProt Q9UEF7 2026, and the biology is reviewed from the aging Prud'homme 2022, renal Kanbay 2024 and neurological Hanson 2021 sides.
Step two, human observation: consistent and correlational. Lower circulating Klotho tracks with kidney disease, vascular calcification and worse cognitive and functional outcomes Kanbay 2024 Hanson 2021. Every one of those is an association, and the direction is genuinely ambiguous: kidney damage lowers Klotho, so a low Klotho in a sick person may be a consequence rather than a cause.
Step three, the one human interventional result, and it comes from a different drug class. Orally-active, clinically-translatable senolytics restored alpha-Klotho in mice and in humans Zhu 2022. That is the strongest evidence anywhere that circulating Klotho in a person can be moved by an intervention — and the intervention was dasatinib plus quercetin, not Klotho.
Step four, the product this page is actually about, and here the chain stops. The Vault card describes a long-release recombinant construct carrying an albumin-binding group, with a claimed duration of cellular activity of up to about 19 days — and the card already flags that figure as a vendor claim, not independently published. This page will not repeat it as a pharmacokinetic fact. There is no published human pharmacokinetic study of any recombinant Klotho preparation, no published human dose, and no clinical trial result.
Where the chain breaks, and it breaks in an unusually concrete way. (1) Size and glycosylation. Klotho's activity depends on correct folding and glycosylation of a 1,012-residue protein UniProt Q9UEF7 2026; a product's identity therefore cannot be established by peptide-purity methods at all. (2) Route. A protein of this size is not orally available and does not reach the brain from the periphery. (3) Immunogenicity. Repeated dosing of a recombinant human protein with a non-native albumin-binding modification is a textbook setup for anti-drug antibodies, which would neutralize it and could in principle cross-react with the endogenous protein. (4) Assay. Circulating soluble Klotho measurement is notoriously assay-dependent, which is why cross-study comparisons of absolute values are unreliable.
What would have to be true, and how you would know it was not
Three predictions. The first is what the FGF23 co-receptor role actually predicts, the second borrows the only human read-out that exists, and the third is the null result to expect.
1. If Klotho is engaging the FGF23 axis, mineral handling moves — and that is a standard blood panel. Klotho with FGF23 drives renal phosphate excretion and suppresses 1,25-dihydroxyvitamin D synthesis Kanbay 2024. So: PTH/calcium and serum phosphate on a CMP, plus vitamin D, at baseline and 12 weeks. A fall in phosphate with a rise in PTH is the mechanistic fingerprint of this axis being engaged, and it is the only prediction on this page that follows directly from established human physiology rather than from an extrapolation.
2. The kidney read-out is the one with the best human grounding. The renal literature is where Klotho biology is strongest Kanbay 2024. Cystatin C and a creatinine-based eGFR from a CMP at baseline and at 6 months. Cystatin C is the better estimate here because Klotho interest concentrates in people whose muscle mass makes creatinine misleading.
3. The falsification test, and the honest expectation is a null. The cognitive claim Hanson 2021 depends on a large glycoprotein reaching the brain, which nothing has shown. A MoCA at baseline and at 6 months is cheap, validated and specific enough to detect a real cognitive change. The prediction of this page is that it will not move — and a person who measures it and finds no change has generated exactly the information the absent literature cannot supply.
What nobody has tested yet
Four things nobody has published, and the first is the one the product depends on.
Nobody has published a human pharmacokinetic study of any recombinant Klotho. No half-life, no bioavailability, no dose-exposure relationship. The card's 19-day figure is a vendor claim on its face. Until a pharmacokinetic study exists, nobody — including a seller — knows what a dose of this does in a person.
Nobody has run a clinical trial of Klotho supplementation in any indication. The strongest human data on raising Klotho comes from giving something else entirely Zhu 2022. A phase 1 safety and pharmacokinetic study in chronic kidney disease — the population with the clearest deficiency and the clearest endpoint Kanbay 2024 — is the obvious first trial and it has not been done.
Nobody has settled whether low Klotho is cause or consequence. The association with kidney disease, calcification and cognitive decline is consistent Kanbay 2024 Hanson 2021 and the causal direction is unresolved. Mendelian randomization using KL variants is the study design that would separate them without a trial, and it has not been applied at scale to these endpoints.
Nobody has tested whether raising Klotho by an indirect route reproduces the benefit. Senolytics raise it Zhu 2022; exercise and some existing drugs are reported to. If the benefit of Klotho can be obtained without injecting a 1,012-residue protein, that is by far the most practical version of this hypothesis, and nobody has run the trial that would show it.
Klotho — its own safety story, not its class's
No recombinant Klotho preparation is approved anywhere, and none has been through a published human trial. The class block above is written for small molecules and peptides, and this is neither.
The risk that is specific to a protein of this size is immunogenicity, and it is not a small one. Repeated injection of a recombinant human protein — particularly one carrying a non-native modification such as an albumin-binding group — commonly raises anti-drug antibodies. The consequence is not only loss of effect: antibodies raised against a modified version of a human protein can in principle cross-react with the endogenous one, which for a protein with a role in mineral handling and kidney function Kanbay 2024 is a serious theoretical harm. Nobody has measured whether it occurs, because nobody has run the study.
The mineral-axis risk follows from the mechanism. Klotho with FGF23 drives phosphate excretion and suppresses active vitamin D Kanbay 2024. Excess activity of that axis is a recognized cause of phosphate wasting and bone disease. This is not a hypothetical class of harm — it is the pathophysiology of FGF23-excess disorders, arrived at from the other end.
The growth-signaling question cuts the other way. Klotho dampens insulin/IGF-1 signaling Prud'homme 2022, which is the basis of the longevity interest and is also a change to a pathway governing tissue growth and repair. Chronic pharmacological suppression of it has no human safety data at all.
Product identity cannot be verified by the usual means. Klotho's function depends on correct folding and glycosylation across 1,012 residues UniProt Q9UEF7 2026. A certificate of analysis reporting mass or peptide purity says nothing about whether the protein is folded, glycosylated or active, and a misfolded preparation is inert at best and immunogenic at worst.
What this page will not do. Print a dose, or repeat the vendor's duration claim as pharmacokinetics. Klotho is real biology with a genuine human literature in nephrology and a genuine hypothesis in neurology; the injectable product is a recombinant protein with no published human study of any kind, and those two sentences are the whole page.
Sources read for this page
- UniProt Consortium. UniProtKB Q9UEF7 (KLOT_HUMAN) — Klotho, gene KL, EC 3.2.1.31: 1012 amino acids, signal peptide 1-33, transmembrane helix 982-1002, and two glycosyl hydrolase family 1 regions at 57-506 and 515-953. UniProt Knowledgebase, reviewed entry, release 2026
- Kanbay M, et al. Klotho: a potential therapeutic target in aging and neurodegeneration beyond chronic kidney disease-a comprehensive review from the ERA CKD-MBD working group. Clinical Kidney Journal 2024 · PMID 38213484
- Prud'homme GJ, Kurt M, Wang Q. Pathobiology of the Klotho Antiaging Protein and Therapeutic Considerations. Frontiers in Aging 2022 · PMID 35903083
- Hanson K, Fisher K, Hooper NM. Exploiting the neuroprotective effects of alpha-klotho to tackle ageing- and neurodegeneration-related cognitive dysfunction. Neuronal Signaling 2021 · PMID 34194816
Klotho — safety, predicted from mechanism
Predicted from mechanism, not from a human safety trial. How that reasoning works →
What the mechanism predicts
Derived from the molecule, not a trial.
- Alpha-Klotho is the obligate co-receptor that lets FGF23 signal, and that gives the first prediction a specific, checkable shape: more klotho means more FGF23 signaling, and FGF23 signaling makes the kidney excrete phosphate and suppresses activation of vitamin D. The human diseases of excess FGF23 signaling are diseases of low phosphate, low calcitriol and soft bone. That is not a theoretical worry — it is the axis the molecule sits on.
- Klotho also dampens insulin/IGF-1 and Wnt signaling and raises resistance to oxidative stress. Reduced IGF-1 signaling is much of the longevity argument, and it is the same reason to think about wound healing, growth and glucose handling rather than assume they are unaffected.
- It is a large recombinant protein given by injection, which brings the risk every injected therapeutic protein brings: immunogenicity. Anti-drug antibodies can neutralize the injected protein, and in the worst version cross-react with the endogenous one — leaving someone with less klotho signaling than they started with. That is a mechanism-level concern common to recombinant proteins, and nothing about this one exempts it.
What has actually been reported
- Nothing in humans. There is no approved klotho product, no published clinical trial of recombinant klotho, and therefore no human safety data of any kind.
- What exists is animal, and some of it is genuinely interesting: klotho-deficient mice age prematurely, klotho-overexpressing mice live longer, and a single low dose of recombinant klotho improved cognitive performance in aged rhesus macaques. A primate result is a reason to run a trial. It is not a substitute for one.
- Low klotho in humans is a well-described feature of ageing and of chronic kidney disease. That is an association with disease, not evidence that raising it is safe or that it does anything.
How to reduce the risk
Same mechanism as the prediction.
- Get phosphate, calcium, PTH and vitamin D before you start, and again after. One predicted abnormality, one cheap panel; there is no excuse for not having it.
- Treat identity and purity as open questions rather than assumptions, because for a recombinant protein they are the questions.
- Run it alone and decide in advance what result would make you stop. With no human data, your own before-and-after is the only evidence that will ever exist for you.
What it does to your bloodwork
A fact about the assay.
- Phosphate, calcium, PTH and 25-OH vitamin D. This is the axis the mechanism acts on and hypophosphatemia is the specific predicted abnormality — cheap to check and silent until it is not.
- eGFR and creatinine, because klotho biology is kidney biology and the kidney is where the phosphate handling happens.
- Soluble klotho can be measured, but the available assays are research tools and results are not comparable between them. Treat a number from one as an experiment rather than a diagnosis.
What it overlaps with
- Anything else acting on phosphate and vitamin D handling — phosphate binders, high-dose vitamin D, calcium supplements — is arriving at the same axis from another direction.
Don't run this if
- Chronic kidney disease or any disordered mineral metabolism, without a clinician. Phosphate, calcium, PTH and vitamin D are already deranged there, and this compound acts on exactly that axis.
- Pregnancy and breastfeeding — no data, and this is a developmental signaling pathway.
- Active malignancy. The anti-Wnt and anti-IGF-1 direction is arguable both ways, and 'arguable both ways' is not reassurance.
The honest unknown
- Whether an injected protein this size reaches the compartments the claims depend on. The primate cognition result raises the question of how a large protein produces a central effect, and the answer is not settled.
- Whether the vial contains klotho at all. 'alphaKlothoLR' is not a pharmacopoeial name, there is no reference standard a buyer can check against, and this protein's function depends on glycosylation — which is exactly the property a cheap expression system gets wrong. Unproven is not ineffective; unverified is a separate problem on top of it.
Not medical advice. If you take prescription medication or have a diagnosed condition, check this with a pharmacist or doctor.
Klotho — interference & stacking
Predicted from mechanism, not from an interaction study. How mechanism-predicted claims are made →
What Klotho moves on your bloodwork
Expected direction, not a measured one.
- hs-CRP (High-Sensitivity C-Reactive Protein) — ↓ expected to fall
Where these work, systemic inflammation is the plausible readout.
What to do: hs-CRP is cheap and moves. Baseline and 12 weeks. - HbA1c (Hemoglobin A1c) — ↓ expected to fall
Improved mitochondrial and metabolic function should show here if the effect is real at all.
What to do: The honest use of these markers is as a falsification test: if nothing moves in 12 weeks, the compound is not doing much for you. - Comprehensive Metabolic Panel (CMP) — ◆ worth watching
Liver and kidney function — the standard baseline for anything run long term.
What to do: Twice a year is enough on a stable protocol.
This class is where honest expectation-setting matters most: the markers above are how you find out whether anything happened, and for most of these compounds that question is genuinely open.
- How to work up to it, and when not to
- When to take it, and why that window
- Cycle length
- Time off between cycles
- Fasted or fed, and when in the day
- Needle gauge and injection site
- Coach Cam's personal notes
- Which compounds push the same lever, and why the dose adds up faster than people count
- What blunts it — the stacks that waste your money
- What compounds the risk, so a side effect arrives sooner than any one of them suggests
- Coach Cam's read on running it alongside the rest of your protocol
Everything above is free and stays free. Skool is where it becomes a plan — Klotho in an order, with the rest of what you're running.
Unlock in Skool — $10/mo →Bloodwork to run alongside Klotho
Baseline first, then again at 8–12 weeks.
| Marker | What it’s watching for |
|---|---|
| hs-CRP (High-Sensitivity C-Reactive Protein) | Chronic low-grade inflammation is the process most of these target |
| ApoB (Apolipoprotein B) | Counts the particles that actually cause plaque, unlike LDL-C |
| HbA1c (Hemoglobin A1c) | Glycation, which is the other half of the ageing story |
| Comprehensive Metabolic Panel (CMP) | Liver and kidney — the two organs that clear everything you take |
| Complete Blood Count (CBC) with Differential | The cheapest broad screen there is |
The Longevity Baseline panel covers these in one order — 13 markers, $219.10 with the discount applied.
Check results you already have → · All 103 markers A–Z
Klotho — frequently asked questions
What is Klotho?
Klotho (alpha-Klotho, sKlotho, long-release recombinant Klotho) is a longevity & bioregulators research compound. Alpha-Klotho is an anti-ageing protein made mostly in the kidney and the choroid plexus. A soluble form is shed into blood and CSF. It is the obligate co-receptor that lets FGF23 signal, which is how it governs phosphate and vitamin D handling, and separately it dampens insulin/IGF-1 and Wnt signaling and raises resistance to oxidative stress. Klotho falls with age and falls further in chronic kidney disease.
Is the full Klotho protocol on this page?
The reported research dose is on this page, along with how Klotho works and the evidence behind it. The protocol — how to work up to it, frequency, cycle length, time off, what not to stack it with and Coach Cam's notes — is inside Skool.
What is the half-life of Klotho?
Klotho has an approximate half-life of Native soluble Klotho is cleared within hours; the LR construct carries an albumin-binding group intended to hold cellular activity for up to ~19 days (vendor claim, not independently published), which is part of what determines how often it's dosed.
What's the evidence behind Klotho?
Current evidence level: Theoretical — no human administration data. Klotho is offered for research purposes only and is not an approved medicine.
What Klotho is used for
Klotho appears under 1 goal in the goal router.
Related Longevity & Bioregulators compounds
Where this goes next
The pages here are the frameworks. The protocols — the dosing, the order to correct things in, the week-by-week schedule and what to retest — are inside Skool.